Sun, 2014-10-19
Pharming And Swedish Orphan Biovitrum Amend And Extend Ruconest Distribution Agreement

Biotech company Pharming Group NV and Swedish Orphan Biovitrum AB (Sobi”) has announced the amendment and extension of their Ruconest distribution agreement. Effective immediately, Pharming will focus on direct commercialization in Austria, Germany and Netherlands, and Sobi will extend its Ruconest sales territory with the addition of Azerbaijan, Belarus, Georgia, Kazakhstan, Russia, Serbia and Ukraine

Tue, 2014-10-07
BioCryst Announces Late Breaker Presentation of OPuS-1 Phase 2 Trial Results at the 23rd EADV Congress

BioCryst Pharmaceuticals, Inc., today announced that results from its successful OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in patients with HAE will be presented as a late-breaker oral presentation at the 23rd EADV Congress taking place in Amsterdam October 8-12, 2014.

Mon, 2014-09-22
Dyax Corp. Highlights Recent Progress in Licensing and Funded Research Portfolio

Dyax Corp. today highlighted recent progress and upcoming milestones in its Licensing and Funded Research Portfolio (LFRP), including, most recently, licensee Eli Lilly and Company's announcement of the fourth positive Phase 3 study outcome for CYRAMZA (ramucirumab). Product candidates in Dyax's LFRP are eligible for royalties on the first ten years of commercial sales from each antibody program, as well as certain milestone payments.The LFRP currently has 10 product candidates in clinical trials and multiple preclinical programs.

Mon, 2014-09-22
Sobi opens the company's new North American office in Massachusetts

The Dutch biotechnology company, Pharming NV has developed the recombinant C1 inhibitor product Ruconest. This product is marketed in Europe and some other countries through their partner Swedish Orphan Biovitrum (Sobi) - and Sobi today formally opened the company's new North American office in Massachusetts.

Mon, 2014-09-15
Dyax Announces Issuance of Two Key U.S. Patents for DX-2930

Dyax Corp. today announced that the U.S. Patent and Trademark Office (USPTO) has issued two new patents related to DX-2930, an investigational fully human monoclonal antibody inhibitor of active plasma kallikrein.

Teaser 4, 2nd row left, in news section

United We Stand Strong!

HAEi cares about you. We encourage patients to get organized - because "United We Stand Strong".

HAE International - Thumb 7HAE International - Thumb 7Become a National Member Organization (NMO). We are here to help you in founding a National Member Organization. Follow our step-by-step model. It doesn't have to be a difficult task creating the best foundation for patients in your country. Contact us for more information here

HAE International - Thumb 4HAE International - Thumb 4

Starting a National Patient Group (NPG). If you are interested in doing more around HAE - but don't feel that starting a full NMO is the right option here and now. You should maybe consider becoming a contact patient (NPG) for your country. Contact us here

Both NMO's and NPG's enjoy free membership of HAEi. Also we can help you host your country specific website under the global umbrella of HAEi.


Sat, 2014-12-06 09:00 - Tue, 2014-12-09 15:00

WAO International Scientific Conference 2014

Venue: SulAmérica Convention Center, Av Paulo de Frontin, 1 - New City, Centro Rio de Janeiro - RJ, Brazil
Language: English

Advancing the borders of allergy: From treatment to prevention by targeting the environment, infections and the susceptible patient

We are delighted to welcome you to participate in the WAO International Scientific Conference 2014 (WISC 2014) and the XLI Annual Congress of the Brazilian Association of Allergy and Immunology (ASBAI) in Rio de Janeiro, Brazil, 6-9 December 2014.

Thu, 2014-11-06 09:00 - Mon, 2014-11-10 16:00

ACAAI - 2014 Annual Scientific Meeting

Venue: Georgia World Congress Convention Center, Atlanta, GA, United States of America
Language: English

Plan to join your colleagues at the 71st ACAAI Annual Scientific Meeting in Atlanta, Nov. 6-10. Broaden your expertise, enhance your practice management skills and improve patient care.

For more information please visit: ACAAI Annual Meeting 2014

Fri, 2014-10-24 13:00 - Sun, 2014-10-26 12:30

International scientific conference on Expanding Boundaries of our HAE Knowledge

Venue: Bethesda Marriott, 5151 Pools Hill Road, Bethesda, MD 20814, USA
Language: English

This first international scientific meeting on HAE, sponsored by National Institutes of Health in conjunction with the US HAEA Angioedema Center at UCSD, will bring together experts in all types of angioedema, as well as clinical medicine to discuss the emerging basic science.

Read more about the conference here


Homepage Teaser 6, 2nd row right

HAE Global Community

Be part of the HAEi Community

HAEi is here to help you. Therefore we have created the HAEi Community that gives you all the bells and whistles you know from other social media (such as Facebook) and even a very sophisticated Forum, where you can discuss with fellow HAE patients and care givers. The only difference is - that here your information stays safe - and will only be shared with other HAE patients and care givers. If you are a HAE patient or directly related to a HAE patient we urge you to register today - and become an important member of our community

Help yourself and stay updated by registering already today - then you will be the first to know.....

Do you have Questions?
You can find answers on our FAQ-Page or
send us an e-mail to:
or go to the contact form page

Experiencing browser problems?

Our website is working properly on most web browsers. However, we know that the site will not perform correctly on Microsoft Internet Explorer version 6 and earlier! So if you are using Internet Explorer from Microsoft please ensure that you have version 7 or higher!

See the video from the 2012 HAE Global Conference in Copenhagen

Click here

HAEDAYHAEDAYLook out for next hae day :-) on 16 May 2014